Autoantibody Biomarker Discovery

ADR Prediction

Diseases Diagnostics

Predicting Vaccine Responsiveness

Autoantibody Biomarker Discovery

Autoantibodies are produced by the immune system and have been identified as important biomarkers in cancer, auto-immune and neurodegenerative diseases. Its appearance may precede disease symptoms by many years and due to the inherent amplification of the immune system, they are readily detectable. Their unique potential for pre-symptomatic and early diagnosis of disease makes autoantibodies effective tools for biomarker discovery.

Autoantibodies can assist in disease prediction and prognosis, which translates to more effective antibody-based therapeutics once combined with novel bioinformatics methods and algorithms.  This results in an increased likelihood of the development of new tests that offer the probability of earlier diagnosis, improved disease prediction and stratification of patients.

For the purposes of this application, we recommend the usage of the Standard Immunome protein array for exploratory purposes. Custom Array slides are also useful if you need any additional types or isoforms of certain proteins on the array.

Adverse Drug Reaction (ADR) Prediction

Immunotherapies are changing the outlook for many cancer patients. For instance, inhibition of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed death 1 (PD1) immune checkpoints has been proven to activate the immune system. The administration of inhibitors targeting these checkpoints, both individually, and in combination, have shown promising results for the treatment of melanoma and non-small cell lung cancer.

However, the complex and diverse nature of cancers mean that the effectiveness of the treatments varies both by type of cancer, and by patient. In fact, some patients, depending on their physiological makeup, may suffer from immune-related adverse events (irAE) from these therapies, which can include autoimmune responses. Therefore, profiling immunotherapy-related immuno-toxicity in cancer patients could serve as a tool to better predict the correct dosage and combination, as well as patient’s response to treatment. This could help lessen the adverse effect of irAE in immunotherapies, while maintaining its’ benefits.

For this application, we recommend the usage of the Standard Immunome protein array to examine the autoantibody signatures of patients. However, it can be modified to suit your needs if any additional types or isoforms of certain proteins would be needed in the array.

Infectious Diseases Diagnostics

Rapid, high-throughput and sensitive diagnosis of infectious diseases by using custom arrays spotted with viral and bacterial proteins. Sengenics’ Immunome protein array platform can be customised to include viral/bacterial/parasitic antigens that can be used against human samples in order to screen infections. For the purposes of this application, we recommend the usage of the Custom Array service as described in our Solutions page.

Predicting Vaccine Responsiveness (Vaccine Screening)

Screening or testing of new vaccines via quantification of interaction between viral proteins and their receptors on human cells, to include measurement of disruption by new vaccines. Vaccine responsiveness can be predicted via receptor binding assays using the Immunome protein array platform. The Immunome protein array also allows you to:

  • examine the types of adverse effects that could manifest in patients

  • differentiate low-value and high value vaccine formulations

  • plan your research cycle accordingly.

For the purposes of this application, we recommend the usage of the Custom Array slides.

For other types of research, please contact us to help you determine the best solution to your research.

Other Immunome Applications

Functional protein interaction assays

Allows us to elucidate the roles of various different proteins in the context of its interaction with other proteins, peptides, DNA, RNA and small molecules.


  • Kinase inhibition assays

  • Identification of off-target interactions

  • Identification of their mechanisms of action

Protein-small molecules

  • Discovery of novel protein connections

  • Predicting new interactome models

  • Mapping protein pathways


  • Quantification of DNA/RNA binding efficiency of proteins

  • Study of DNA/RNA repair mechanisms

  • Anti-viral activity research

Predictive toxicology

Adverse drug reactions are an issue for the pharmaceutical industry, patients and hospitals because of the potential for injury, disability and loss of life. Autoantibody profiling allows you to:

  • predict the severity of adverse effects that could manifest in patients

  • predict the right dosage and/or combination

  • predict overall response of patients to the drug

An example use case for the Immunome protein array platform in relation to predictive toxicology is the Iressa case study. More information on this study can be found here.